Proteomic Analysis of Anticancer Effect of Myo-inositol in Human Prostate Cancer (DU-145) Cell Line

Islam, Mohammad Jahidul; Muntaha, Sidratul; Masum, Md Mohiuddin; Nowshin, Sazia; Salam, Sabia; Haque, Mominul; Wint Zaw, Myo; Jahan, Shahriar

doi:10.31557/APJCP.2024.25.12.4447

Proteomic Analysis of Anticancer Effect of Myo-inositol in Human Prostate Cancer (DU-145) Cell Line

Document Type : Research Articles

Authors

¹ Department of Pharmacology. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

² Department of Biochemistry, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

³ Department of Anatomy, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

⁴ Department of Surveillance & Immunization, World health organization (WHO), Dhaka. Bangladesh.

⁵ National Institute of Ophthalmology & Hospital, Dhaka, Bangladesh.

⁶ Department of Anatomy, Popular Medical College, Dhaka, Bangladesh.

⁷ Department of Biochemistry, University of Cyberjaya, Malaysia.

⁸ Department of Molecular Biology, EW Villa Medica, Dhaka, Bangladesh.

10.31557/APJCP.2024.25.12.4447

Abstract

Objective: This study investigated the potential anticancer properties of Myo-inositol on the DU-145 prostate cancer cell line. Methods: The DU-145 cells have been treated to different doses of Myo-inositol in order to ascertain the half-maximal inhibitory concentration (IC50) using the trypan blue exclusion assay. The impact of Myo-inositol on proteomic profiles was evaluated using 2D gel electrophoresis and liquid chromatography-mass spectrometry (LC-MS). Results: Myo-inositol significantly reduced DU-145 cell viability with an IC50 of 0.06 mg/ml (p<0.05). Proteomic analysis highlighted marked differences in protein expression between treated and untreated cells, particularly in proteins related to cytoskeletal regulation, apoptosis, and stress response. LC-MS further identified significant alterations in protein profiles, with suppression of proteins like Annexin A2 and Cofilin-1-A in controls, and upregulation of proteins such as Rho GTPase-activating protein, Apoptotic protease-activating factor 1 (APAF1), and TNF receptor-associated factor 2 (TRAF2) in treated samples (p<0.001), indicating modulation of key signaling pathways involved in tumor suppression and oncogenesis. Conclusion: Myo-inositol exhibits anticancer properties in prostate cancer cells by impacting cell viability and altering protein expression. While promising as an adjunctive treatment, further studies are needed to understand its mechanisms and potential in combination therapies for managing CRPC.

Keywords

Main Subjects